

Paul J Martin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1940989/publications.pdf>

Version: 2024-02-01

177
papers

24,519
citations

9786

73
h-index

7348

152
g-index

177
all docs

177
docs citations

177
times ranked

15822
citing authors

#	ARTICLE	IF	CITATIONS
1	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 945-956.	2.0	3,213
2	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 389-401.e1.	2.0	2,636
3	Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2010, 363, 2091-2101.	27.0	1,335
4	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. <i>Nature Genetics</i> , 2010, 42, 508-514.	21.4	1,132
5	Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. <i>Blood</i> , 2011, 117, 3214-3219.	1.4	544
6	Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. <i>Blood</i> , 2003, 102, 756-762.	1.4	531
7	Endothelial Cells of Hematopoietic Origin Make a Significant Contribution to Adult Blood Vessel Formation. <i>Circulation Research</i> , 2000, 87, 728-730.	4.5	507
8	First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1150-1163.	2.0	506
9	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 252-266.	2.0	445
10	Optimizing Outcome After Unrelated Marrow Transplantation by Comprehensive Matching of HLA Class I and II Alleles in the Donor and Recipient. <i>Blood</i> , 1998, 92, 3515-3520.	1.4	442
11	Histopathologic Diagnosis of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 31-47.	2.0	427
12	Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. <i>Blood</i> , 2002, 100, 415-419.	1.4	403
13	Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 3249-3256.	1.6	361
14	Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose. <i>Blood</i> , 1997, 89, 4226-4235.	1.4	358
15	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 211-234.	2.0	328
16	Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. <i>Human Immunology</i> , 1990, 29, 79-91.	2.4	325
17	Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2010, 28, 1011-1016.	1.6	321
18	Ancillary Therapy and Supportive Care of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 375-396.	2.0	316

#	ARTICLE	IF	CITATIONS
19	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 984-999.	2.0	293
20	How we treat chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 606-615.	1.4	275
21	Duration of immunosuppressive treatment for chronic graft-versus-host disease. <i>Blood</i> , 2004, 104, 3501-3506.	1.4	269
22	Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. <i>Blood</i> , 2002, 100, 48-51.	1.4	263
23	Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-CD25 Lymphocyte Globulin to Assess Impact on Chronic Graft-versus-Host Disease-free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4011.	1.6	258
24	Involvement of the B-lymphoid system in chronic myelogenous leukaemia. <i>Nature</i> , 1980, 287, 49-50.	27.8	237
25	Airflow Obstruction after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 208-214.	5.6	233
26	NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 589-603.	2.0	228
27	Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. <i>Blood</i> , 2009, 114, 702-708.	1.4	218
28	Graft-versus-Host Disease and Graft-versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1530-1538.	1.6	197
29	Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. <i>Blood</i> , 2011, 118, 4242-4249.	1.4	196
30	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 761-767.	2.0	195
31	Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. <i>Blood</i> , 2003, 102, 820-826.	1.4	190
32	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1167-1187.	2.0	182
33	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. <i>Blood</i> , 2016, 127, 1502-1508.	1.4	174
34	A phase I/II trial of iodine-131-anti-CD20 (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. <i>Blood</i> , 2000, 96, 2934-2942.	1.4	173
35	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 491-505.	2.0	165
36	Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. <i>Annals of Internal Medicine</i> , 2020, 172, 229.	3.9	157

#	ARTICLE	IF	CITATIONS
37	Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 710-716.	2.0	151
38	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2009, 113, 5074-5082.	1.4	143
39	Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 320-327.	2.0	142
40	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 780-792.	2.0	124
41	Thalidomide for treatment of patients with chronic graft-versus-host disease. <i>Blood</i> , 2000, 96, 3995-3996.	1.4	122
42	Correlation Between Disparity for the Minor Histocompatibility Antigen HA-1 and the Development of Acute Graft-Versus-Host Disease After Allogeneic Marrow Transplantation. <i>Blood</i> , 1999, 94, 2911-2914.	1.4	121
43	Biomarker Panel for Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 2583-2590.	1.6	118
44	Use of Fluid-Ventilated, Gas-Permeable Scleral Lens for Management of Severe Keratoconjunctivitis Sicca Secondary to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1016-1021.	2.0	115
45	Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. <i>Blood</i> , 2009, 113, 2888-2894.	1.4	115
46	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 449-455.	2.0	113
47	An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. <i>Blood</i> , 2006, 108, 749-755.	1.4	112
48	Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. <i>Blood</i> , 2015, 126, 113-120.	1.4	110
49	Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease. <i>Blood</i> , 2017, 129, 791-798.	1.4	109
50	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1343-1359.	2.0	105
51	Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. <i>Blood</i> , 2012, 120, 2545-2552.	1.4	101
52	Hematopoietic stem cell transplants from unrelated donors. <i>Immunological Reviews</i> , 1997, 157, 141-151.	6.0	99
53	Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 384-387.	2.0	98
54	Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. <i>British Journal of Haematology</i> , 1989, 72, 567-572.	2.5	95

#	ARTICLE	IF	CITATIONS
55	A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 835-844.	2.0	95
56	Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. <i>Blood</i> , 2014, 123, 786-793.	1.4	94
57	Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 5098-5103.	1.4	93
58	Evaluation of published single nucleotide polymorphisms associated with acute GVHD. <i>Blood</i> , 2012, 119, 5311-5319.	1.4	92
59	Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. <i>Blood</i> , 2014, 124, 3221-3227.	1.4	92
60	Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. <i>Nature Genetics</i> , 2009, 41, 1341-1344.	21.4	91
61	Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 573-584.	2.0	88
62	PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. <i>Journal of Clinical Investigation</i> , 2017, 127, 1960-1977.	8.2	88
63	Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2014, 124, 1363-1371.	1.4	86
64	Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. <i>Blood</i> , 2012, 120, 2796-2806.	1.4	84
65	Late Cardiovascular Complications after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 794-800.	2.0	84
66	Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e409-e418.	4.6	84
67	Validation of Measurement Scales in Ocular Graft-versus-Host Disease. <i>Ophthalmology</i> , 2012, 119, 487-493.	5.2	83
68	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. <i>Blood</i> , 2014, 124, 287-295.	1.4	83
69	Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. <i>Blood</i> , 2016, 127, 3082-3091.	1.4	83
70	Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation. <i>Blood</i> , 2017, 129, 2693-2701.	1.4	80
71	Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. <i>Haematologica</i> , 2012, 97, 451-458.	3.5	77
72	A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1323-1330.	2.0	76

#	ARTICLE	IF	CITATIONS
73	Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 337-344.	2.0	76
74	Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2011, 118, 456-463.	1.4	75
75	Treatment of chronic graft-versus-host disease: Past, present and future. <i>The Korean Journal of Hematology</i> , 2011, 46, 153.	0.7	74
76	Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. <i>Blood</i> , 2016, 127, 2249-2260.	1.4	74
77	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 545-557.	1.2	72
78	A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2016, 22, 319-327.	7.0	68
79	Role of CD28 in Acute Graft-Versus-Host Disease. <i>Blood</i> , 1998, 92, 2963-2970.	1.4	62
80	Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 777-784.	2.0	62
81	Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1418-1424.	2.0	62
82	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 817-835.	1.2	62
83	A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus-Host Disease (cGVHD) Therapeutic Response Measures: Feasibility, Interrater Reliability, and Minimum Detectable Change. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1619-1629.	2.0	61
84	HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1382-1387.	2.0	60
85	Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1594-1601.	2.0	60
86	Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. <i>Nature Communications</i> , 2017, 8, 978.	12.8	58
87	Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 2340-2346.	1.4	55
88	Secondary Treatment of Acute Graft-versus-Host Disease: A Critical Review. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 982-988.	2.0	52
89	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 360-367.	1.4	52
90	Assessment of Joint and Fascia Manifestations in Chronic Graft-versus-Host Disease. <i>Arthritis and Rheumatology</i> , 2014, 66, 1044-1052.	5.6	50

#	ARTICLE	IF	CITATIONS
91	Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 555-562.	2.0	50
92	Homotypic aggregation of human cell lines by HLA class II-, class Ia- and HLA-G-specific monoclonal antibodies. <i>European Journal of Immunology</i> , 1991, 21, 2121-2131.	2.9	49
93	Molecular diversity of the HLA-D locus in unrelated marrow transplantation. <i>Tissue Antigens</i> , 1994, 44, 93-99.	1.0	49
94	Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1380-1384.	2.0	49
95	Biology of Chronic Graft-versus-Host Disease: Implications for a Future Therapeutic Approach. <i>Keio Journal of Medicine</i> , 2008, 57, 177-183.	1.1	49
96	Clinical Benefit of Response in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1517-1524.	2.0	47
97	How I treat steroid-refractory acute graft-versus-host disease. <i>Blood</i> , 2020, 135, 1630-1638.	1.4	46
98	Multi-centre validation of the prognostic value of the haematopoietic cell transplantation-specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2015, 170, 574-583.	2.5	45
99	Polymorphism of HLA-DRA-associated DRB1 genes as defined by sequence-specific oligonucleotide probe hybridization and sequencing. <i>Tissue Antigens</i> , 1991, 38, 169-177.	1.0	44
100	Signal transduction by HLA class II antigens expressed on activated T cells. <i>European Journal of Immunology</i> , 1991, 21, 123-129.	2.9	44
101	Outcomes of Lung Transplantation after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1169-1175.	2.0	43
102	Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. <i>Blood</i> , 2016, 127, 160-166.	1.4	43
103	Bandage Soft Contact Lenses for Ocular Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2002-2007.	2.0	41
104	Reevaluation of the Pretransplant Assessment of Mortality Score after Allogeneic Hematopoietic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 848-854.	2.0	40
105	Association of Plasma CD163 Concentration with De Novo Onset Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1250-1256.	2.0	38
106	Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1679-1686.	2.0	37
107	Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2022, 40, 1174-1185.	1.6	36
108	A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. <i>British Journal of Haematology</i> , 1992, 80, 49-54.	2.5	35

#	ARTICLE	IF	CITATIONS
109	Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. <i>Blood</i> , 2020, 136, 1903-1906.	1.4	34
110	Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1094-1101.	2.0	33
111	Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. <i>Blood</i> , 2016, 128, 2450-2456.	1.4	32
112	Prognostic Utility of Routine Chimerism Testing at 2 to 6 Months after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 352-359.	2.0	29
113	Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2014, 99, 1618-1623.	3.5	29
114	Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2015, 100, 690-695.	3.5	29
115	Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1257-1263.	2.0	29
116	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 729-737.	1.2	29
117	Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80. <i>Frontiers in Immunology</i> , 2018, 9, 3061.	4.8	28
118	Allogeneic Hematopoietic Cell Transplantation following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 792-798.	2.0	27
119	Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 124-132.	2.0	26
120	Evaluation of Thalidomide for Treatment or Prevention of Chronic Graft-versus-host Disease. <i>Leukemia and Lymphoma</i> , 2003, 44, 1141-1146.	1.3	25
121	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 452-466.	1.2	24
122	Adherence of adoptively transferred alloreactive Th1 cells in lung: partial dependence on LFA-1 and ICAM-1. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2000, 279, L583-L591.	2.9	23
123	Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease. <i>Haematologica</i> , 2014, 99, 385-391.	3.5	23
124	Poor Agreement between Clinician Response Ratings and Calculated Response Measures in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1649-1655.	2.0	22
125	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 632-641.	1.2	21
126	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 10-23.	2.0	20

#	ARTICLE	IF	CITATIONS
127	Recipient and donor genetic variants associated with mortality after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 3224-3233.	5.2	20
128	Home Spirometry Telemonitoring for Early Detection of Bronchiolitis Obliterans Syndrome in Patients with Chronic Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 616.e1-616.e6.	1.2	20
129	Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 451-458.	2.0	19
130	Genetic risk factors for sclerotic graft-versus-host disease. <i>Blood</i> , 2016, 128, 1516-1524.	1.4	18
131	Role of the mixed lymphocyte culture (MLC) reaction in marrow donor selection: Matching for transplants from related haploidentical donors. <i>Tissue Antigens</i> , 1994, 44, 83-92.	1.0	17
132	Evaluation of Oral Beclomethasone Dipropionate for Prevention of Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 922-929.	2.0	16
133	Disability Related to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 772-777.	2.0	16
134	MR Imaging Findings in a Neonate With COVID -19-Associated Encephalitis. <i>Pediatric Neurology</i> , 2021, 119, 48-49.	2.1	15
135	Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. <i>Blood Advances</i> , 2017, 1, 2247-2256.	5.2	15
136	Engagement with INSPIRE, an Online Program for Hematopoietic Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1692-1698.	2.0	14
137	Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1424-1431.	2.0	14
138	Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 2409-2417.	5.2	14
139	IL-22-dependent dysbiosis and mononuclear phagocyte depletion contribute to steroid-resistant gut graft-versus-host disease in mice. <i>Nature Communications</i> , 2021, 12, 805.	12.8	14
140	Pitfalls in the Design of Clinical Trials for Prevention or Treatment of Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 31-36.	2.0	13
141	Pilot study of lithium to restore intestinal barrier function in severe graft-versus-host disease. <i>PLoS ONE</i> , 2017, 12, e0183284.	2.5	13
142	The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 448-451.	1.2	13
143	Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. <i>Blood Advances</i> , 2019, 3, 2764-2777.	5.2	12
144	Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity. <i>Blood</i> , 2021, 137, 2243-2255.	1.4	12

#	ARTICLE	IF	CITATIONS
145	Winning the battle of graft versus host. <i>Nature Medicine</i> , 2000, 6, 18-19.	30.7	11
146	CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 405-411.	2.0	11
147	Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. <i>Blood Advances</i> , 2020, 4, 40-46.	5.2	11
148	HLA-DR molecules enhance signal transduction through the CD3/Ti complex in activated T cells. <i>Tissue Antigens</i> , 1991, 38, 72-77.	1.0	10
149	HLA-DRB1 frst domain sequences of two new DR11 alleles and one novel DR4 allele. <i>Tissue Antigens</i> , 1993, 42, 533-535.	1.0	9
150	Pathogenic neutrophils in acute GVHD. <i>Blood</i> , 2018, 131, 1774-1775.	1.4	9
151	Interleukin-23 receptor signaling by interleukin-39 potentiates T cell pathogenicity in acute graft-versus-host disease. <i>American Journal of Transplantation</i> , 2021, 21, 3538-3549.	4.7	9
152	Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. <i>Blood Advances</i> , 2021, 5, 4549-4559.	5.2	8
153	Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 759.e1-759.e8.	1.2	8
154	The positive association of Association for Academic Surgery membership with academic productivity. <i>Journal of Surgical Research</i> , 2016, 205, 163-168.	1.6	7
155	Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2021, 138, 1628-1636.	1.4	7
156	Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway. <i>Leukemia</i> , 2022, 36, 1907-1915.	7.2	7
157	Front Line Treatment of Chronic Graft versus Host Disease. , 2009, , 124-133.		6
158	The impact of members of the Society of University Surgeons on the scholarship of American surgery. <i>Surgery</i> , 2016, 160, 47-53.	1.9	6
159	Impact of clinical fellowships on academic productivity in departments of surgery. <i>Surgery</i> , 2016, 160, 1440-1446.	1.9	6
160	Sitagliptin to Prevent Acute Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2021, 384, 70-71.	27.0	5
161	Murine Models Provide New Insights Into Pathogenesis of Chronic Graft-Versus-Host Disease in Humans. <i>Frontiers in Immunology</i> , 2021, 12, 700857.	4.8	5
162	Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplant and investigation into BOS pathogenesis. <i>Transplantation and Cellular Therapy</i> , 2022, , .	1.2	5

#	ARTICLE	IF	CITATIONS
163	The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2468-2473.	2.0	4
164	A Model of Minor Histocompatibility Antigens in Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 782152.	4.8	4
165	Bone marrow transplantation for COVID-like humoral immune deficiency associated with red cell aplasia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1856-1859.	1.5	3
166	Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. <i>Blood</i> , 1997, 89, 3880-3887.	1.4	3
167	Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin. <i>Bone Marrow Transplantation</i> , 2021, , .	2.4	2
168	Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1869-1874.	2.0	1
169	Genetic Variants Associated with Inflammatory Bowel Disease and Gut Graft-versus-host Disease. <i>Blood Advances</i> , 2021, 5, 4456-4464.	5.2	1
170	Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation. , 0, , 365-375.		1
171	Rare Variant Genetic Association Study for Transplant-Associated Thrombotic Microangiopathy (TA-TMA) Via Whole Exome Sequencing. <i>Blood</i> , 2021, 138, 745-745.	1.4	1
172	Prediction of outcomes after second-line treatment for acute graft-versus-host disease. <i>Blood Advances</i> , 2022, , .	5.2	1
173	Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	1
174	Educating Radiologists for Self-governance. <i>Academic Radiology</i> , 2018, 25, 540-542.	2.5	0
175	Serious Acute or Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplantation: A Comparison of Myeloablative and Non-Myeloablative Conditioning Regimens.. <i>Blood</i> , 2006, 108, 755-755.	1.4	0
176	Genetic Associations with Immune-mediated Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Blood Advances</i> , 2022, , .	5.2	0
177	Overview of Hematopoietic Cell Transplantation Immunology. , 0, , 129-144.		0